­-- Dr. Mariana Castells, M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating allergic and inflammatory disease on April 25, 2024, at 10:00 a.m. ET --

-- First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy --

CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.

Mast cells are increasingly implicated in the pathogenesis of a wide range of allergic and inflammatory conditions, leading to an acceleration in research into mast cell biology. This webcast will focus on the biology of mast cells, including their essential role as drivers of and contributors to inflammatory responses, their core involvement in biological pathways relevant to an array of allergic and inflammatory diseases, and Blueprint's approach to modulating mast cells and building a pipeline in allergic and inflammatory disease. The webcast will include a presentation and live Q&A.

Title: The powerful mast cell: a promising target for treating allergic and inflammatory diseases

Date: Thursday, April 25, 2024

Time: 10:00 a.m. ET

Presenters:

Guest speaker

• Mariana Castells, M.D., Ph.D., Director, Mastocytosis Center at Brigham and Women's Hospital

Blueprint Medicines speakers

• Fouad Namouni, M.D., President, Research & Development
• Becker Hewes, M.D., Chief Medical Officer
• Percy H. Carter, Ph.D., MBA, Chief Scientific Officer

To access the live webcast, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 814168. A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after each event and will be available thereafter.

Blueprint plans to host the next webcast in the series in the second half of 2024.

About Blueprint Medicines

Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing AYVAKIT®/AYVAKYT® (avapritinib) to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, and oncology including breast cancer, and other solid tumors vulnerable to CDK2 inhibition. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-host-webcast-and-conference-call-highlighting-emerging-opportunities-for-mast-cell-targeted-therapeutics-302113503.html

SOURCE Blueprint Medicines Corporation

Investor Relations Contact: Cassie Saitow, 617.909.3127, ir@blueprintmedicines.com; Media Relations Contact: Andrew Law, 617.844.8205, media@blueprintmedicines.com